Mostra i principali dati dell'item

dc.contributor.authorZazo, Hinojal
dc.contributor.authorColino, Clara I
dc.contributor.authorWarzecha, Klaudia T
dc.contributor.authorHoss, Mareike
dc.contributor.authorGbureck, Uwe
dc.contributor.authorTrautwein, Christian
dc.contributor.authorTacke, Frank
dc.contributor.authorLanao, José M 
dc.contributor.authorBartneck, Matthias
dc.date.accessioned2025-01-20T10:55:24Z
dc.date.available2025-01-20T10:55:24Z
dc.date.issued2017-03
dc.identifier.issn1616-5187
dc.identifier.urihttp://hdl.handle.net/10366/162002
dc.description.abstractThe human immunodeficiency virus (HIV) continues to be a global pandemic and there is an urgent need for innovative treatment. Immune cells represent a major target of virus infection, but are also therapeutic targets. Currently, no antiretroviral therapy targets macrophages, which function as portal of entry and as major long-term deposit of HIV. It has been shown before that human macrophages efficiently internalize gold nanoparticles, a fact which might be used to target them with drug-nanoparticle conjugates. Here, the authors use gold nanocarriers to facilitate delivery of stavudine, a widely used antiretroviral drug, to primary human macrophages. Using an ease-of-use coupling method, a striking potentiation of stavudine intake by macrophages using gold nanocarriers is shown. Further, the carriers induce a specific subtype of proinflammatory activation indicative for antiviral activity of macrophages, which suggests promising novel treatment options for HIV.es_ES
dc.language.isoenges_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectHIV; drug delivery; gold nanoparticles; macrophages; nanocarriers; stavudine.es_ES
dc.subject.meshHIV Infections *
dc.subject.meshMacrophages *
dc.subject.meshHIV-1 *
dc.subject.meshHumans *
dc.subject.meshDrug Delivery Systems *
dc.subject.meshStavudine *
dc.subject.meshMetal Nanoparticles *
dc.titleGold Nanocarriers for Macrophage-Targeted Therapy of Human Immunodeficiency Virus.es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.identifier.doi10.1002/mabi.201600359
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.pmid27748547
dc.identifier.essn1616-5195
dc.journal.titleMacromolecular biosciencees_ES
dc.volume.number17es_ES
dc.issue.number3es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsestavudina *
dc.subject.decssistemas de liberación de medicamentos *
dc.subject.decsinfecciones por VIH *
dc.subject.decshumanos *
dc.subject.decsmacrófagos *
dc.subject.decsnanopartículas metálicas *
dc.subject.decsVIH-1 *


Files in questo item

Thumbnail
Thumbnail

Questo item appare nelle seguenti collezioni

Mostra i principali dati dell'item

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional